472 related articles for article (PubMed ID: 33067414)
21. Recent Advances in the Management of Smoldering Multiple Myeloma.
Madhira BR; Konala VM; Adapa S; Naramala S; Ravella PM; Parikh K; Gentile TC
World J Oncol; 2020 Apr; 11(2):45-54. PubMed ID: 32284772
[TBL] [Abstract][Full Text] [Related]
22. Progress in the Management of Smoldering Multiple Myeloma.
Schmidt TM; Callander NS
Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517
[TBL] [Abstract][Full Text] [Related]
23. Smoldering multiple myeloma: biology, clinical manifestations and management.
Nsiala L; Bobin A; Levy A; Gruchet C; Sabirou F; Gardeney H; Cailly L; Manier S; Moya N; Tomowiak C; Guidez S; Leleu X; Decaux O
Leuk Lymphoma; 2022 Mar; 63(3):518-529. PubMed ID: 34672244
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of smoldering multiple myeloma based on nationwide screening.
Thorsteinsdóttir S; Gíslason GK; Aspelund T; Rögnvaldsson S; Óskarsson JÞ; Sigurðardóttir GÁ; Þórðardóttir ÁR; Viðarsson B; Önundarson PT; Agnarsson BA; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Eyþórsson E; Jónsson Á; Berlanga O; Hultcrantz M; Durie BGM; Löve TJ; Harding S; Landgren O; Kristinsson SY
Nat Med; 2023 Feb; 29(2):467-472. PubMed ID: 36747117
[TBL] [Abstract][Full Text] [Related]
25. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management.
Rajkumar SV
Hematology Am Soc Hematol Educ Program; 2005; ():340-5. PubMed ID: 16304401
[TBL] [Abstract][Full Text] [Related]
26. Smoldering multiple myeloma.
Rajkumar SV; Landgren O; Mateos MV
Blood; 2015 May; 125(20):3069-75. PubMed ID: 25838344
[TBL] [Abstract][Full Text] [Related]
27. Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model.
Hájek R; Sandecka V; Špička I; Raab M; Goldschmidt H; Beck S; Minařík J; Pavlíček P; Radocha J; Heindorfer A; Jelínek T; Stejskal L; Brožová L; Ševčíková S; Straub J; Pika T; Pour L; Maisnar V; Seckinger A; Hose D
Br J Haematol; 2020 Jul; 190(2):189-197. PubMed ID: 32163180
[TBL] [Abstract][Full Text] [Related]
28. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma.
Ravi P; Kumar S; Larsen JT; Gonsalves W; Buadi F; Lacy MQ; Go R; Dispenzieri A; Kapoor P; Lust JA; Dingli D; Lin Y; Russell SJ; Leung N; Gertz MA; Kyle RA; Bergsagel PL; Rajkumar SV
Blood Cancer J; 2016 Jul; 6(7):e454. PubMed ID: 27471870
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
30. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
31. Clinical characteristics and outcomes in biclonal gammopathies.
Mullikin TC; Rajkumar SV; Dispenzieri A; Buadi FK; Lacy MQ; Lin Y; Dingli D; Go RS; Hayman SR; Zeldenrust SR; Russell SJ; Lust JA; Leung N; Kapoor P; Kyle RA; Gertz MA; Kumar SK
Am J Hematol; 2016 May; 91(5):473-5. PubMed ID: 26840395
[TBL] [Abstract][Full Text] [Related]
32. Understanding high-risk smoldering multiple myeloma.
Kreiniz N; Gertz MA
Leuk Lymphoma; 2023; 64(8):1361-1372. PubMed ID: 37229535
[TBL] [Abstract][Full Text] [Related]
33. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
Golombick T; Diamond TH; Manoharan A; Ramakrishna R
Integr Cancer Ther; 2016 Jun; 15(2):183-9. PubMed ID: 27154182
[TBL] [Abstract][Full Text] [Related]
34. New approaches to smoldering myeloma.
Mateos MV; San Miguel JF
Curr Hematol Malig Rep; 2013 Dec; 8(4):270-6. PubMed ID: 23975678
[TBL] [Abstract][Full Text] [Related]
35. Smoldering Multiple Myeloma: Who and When to Treat.
Mateos MV; González-Calle V
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):716-722. PubMed ID: 28709797
[TBL] [Abstract][Full Text] [Related]
36. Classifying ultra-high risk smoldering myeloma.
Waxman AJ; Mick R; Garfall AL; Cohen A; Vogl DT; Stadtmauer EA; Weiss BM
Leukemia; 2015 Mar; 29(3):751-3. PubMed ID: 25371175
[No Abstract] [Full Text] [Related]
37. High-risk smoldering myeloma: Perspective on watchful monitoring.
Leng S; Lentzsch S
Semin Oncol; 2016 Dec; 43(6):697-699. PubMed ID: 28061989
[TBL] [Abstract][Full Text] [Related]
38. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease.
Kastritis E; Terpos E; Moulopoulos L; Spyropoulou-Vlachou M; Kanellias N; Eleftherakis-Papaiakovou E; Gkotzamanidou M; Migkou M; Gavriatopoulou M; Roussou M; Tasidou A; Dimopoulos MA
Leukemia; 2013 Apr; 27(4):947-53. PubMed ID: 23183429
[TBL] [Abstract][Full Text] [Related]
39. Immunoglobulin free light chains and solitary plasmacytoma of bone.
Dingli D; Kyle RA; Rajkumar SV; Nowakowski GS; Larson DR; Bida JP; Gertz MA; Therneau TM; Melton LJ; Dispenzieri A; Katzmann JA
Blood; 2006 Sep; 108(6):1979-83. PubMed ID: 16741249
[TBL] [Abstract][Full Text] [Related]
40. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.
Medina-Herrera A; Vazquez I; Cuenca I; Rosa-Rosa JM; Ariceta B; Jimenez C; Fernandez-Mercado M; Larrayoz MJ; Gutierrez NC; Fernandez-Guijarro M; Gonzalez-Calle V; Rodriguez-Otero P; Oriol A; Rosiñol L; Alegre A; Escalante F; De La Rubia J; Teruel AI; De Arriba F; Hernandez MT; Lopez-Jimenez J; Ocio EM; Puig N; Paiva B; Lahuerta JJ; Bladé J; San Miguel JF; Mateos MV; Martinez-Lopez J; Calasanz MJ; Garcia-Sanz R;
Blood Cancer J; 2024 Apr; 14(1):74. PubMed ID: 38684670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]